Ammann R W, Akovbiantz A, Häcki W, Largiadèr F, Schmid M
Digestion. 1981;21(6):281-9. doi: 10.1159/000198578.
The diagnostic value of the fecal chymotrypsin test (FCT) was reevaluated with regard to (a) proved pancreatic hypofunction of different severity (183 pancreozymin-secretin tests); (b) the final clinical diagnosis, and (c) fecal fat excretion (208 patients with chronic pancreatitis; CP). Progressive pancreatic disease (cancer, CP) was mainly associated with moderate or severe pancreatic hypofunction (119/138; 86.2%) and a low incidence of false-normal FCT values (14/138; 10.1%). Miscellaneous disorders (mainly reversible pancreatic hypofunction) were mainly associated with slight pancreatic hypofunction and a high incidence of false-normal FCT values (17/45; 37.8%). Pancreatic steatorrhea (greater than 10 g/day) was found only in patients with markedly depressed FCT values. Progressive deterioration of pancreatic function was demonstrated by repeated FCT in CP (n = 220).
粪便糜蛋白酶试验（FCT）的诊断价值通过以下方面进行了重新评估：（a）不同严重程度的已证实的胰腺功能减退（183次促胰液素 - 促胰酶素试验）；（b）最终临床诊断；以及（c）粪便脂肪排泄（208例慢性胰腺炎患者；CP）。进行性胰腺疾病（癌症、CP）主要与中度或重度胰腺功能减退相关（119/138；86.2%），FCT值假正常的发生率较低（14/138；10.1%）。其他疾病（主要是可逆性胰腺功能减退）主要与轻度胰腺功能减退相关，FCT值假正常的发生率较高（17/45；37.8%）。仅在FCT值明显降低的患者中发现胰腺性脂肪泻（大于10克/天）。通过对CP患者（n = 220）进行重复FCT，证实了胰腺功能的进行性恶化。
